0000899243-22-011617.txt : 20220318 0000899243-22-011617.hdr.sgml : 20220318 20220318185857 ACCESSION NUMBER: 0000899243-22-011617 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220317 FILED AS OF DATE: 20220318 DATE AS OF CHANGE: 20220318 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Thompson Alexis A. CENTRAL INDEX KEY: 0001851895 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 22753837 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC. STREET 2: 181 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER NAME: FORMER CONFORMED NAME: Thompson Alexis DATE OF NAME CHANGE: 20210317 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-17 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001851895 Thompson Alexis A. C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2022-03-17 4 M 0 2400 A 2400 D Restricted Stock Units 2022-03-17 4 M 0 2400 0.00 D Common Stock 2400 4800 D Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in three equal annual installments after March 17, 2021, so long as the Reporting Person continues as a board member of the Issuer through each vesting date. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). /s/ Miguel Carrillo, Attorney-in-Fact 2022-03-18